• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   Home
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • View Item
  •   Home
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The effect of memantine in harmaline-induced tremor and neurodegeneration

Date
2011
Author
ERTÜRK, SARP
YARDIMOĞLU YILMAZ, MELDA
KÖKTÜRK, Sibel
Akman, Ozlem
Iseri, Pervin K.
KARSON, AYŞE
Gullu, Kemal M.
ATEŞ, NURBAY
Metadata
Show full item record
Abstract
Essential tremor (ET) is one of the most common and most disabling movement disorders among adults. The drug treatment of ET remains unsatisfactory. Additional therapies are required for patients with inadequate response or intolerable side effects. The current study aims to investigate the anti-tremogenic and neuroprotective effects of memantine (NMDA receptor antagonist) on the harmaline model of transient action tremor. The effects of memantine were further compared with ethanol. Three separate groups of male Wistar rats were injected either with saline, ethanol (1.5 gr/kg), or memantine (5 mg/kg) 15 min prior to a single intraperitoneal injection of harmaline (20 mg/kg). Tremor and locomotion were evaluated by a custom-built tremor and locomotion analysis system. After 24 h of harmaline injection, cellular viability, and apoptosis were assessed using crystal violet staining, and caspase-3 immunostaining, respectively. Harmaline caused neuronal cell loss and caspase-3 mediated apoptosis in cerebellar granular and purkinje cells as well as the inferior olivary neurons. Despite a reduction in tremor intensity and duration with ethanol, this compound resulted in cell loss in cerebellum and olivary nucleus. Memantine exhibited neuroprotective efficacy on cerebellar and inferior olivary neurons albeit weaker anti-tremor effect compared to ethanol. In conclusion, anti-tremogenic and neuroprotective effects do not necessarily overlap. Memantine is a potential treatment for ET particularly given its neuroprotective efficacy. (C) 2011 Elsevier Ltd. All rights reserved.
URI
http://hdl.handle.net/20.500.12627/179425
https://doi.org/10.1016/j.neuropharm.2011.05.015
Collections
  • Makale [92796]

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV
 

 


Hakkımızda
Açık Erişim PolitikasıVeri Giriş Rehberleriİletişim
sherpa/romeo
Dergi Adı/ISSN || Yayıncı

Exact phrase only All keywords Any

BaşlıkbaşlayaniçerenISSN

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypesThis CollectionBy Issue DateAuthorsTitlesSubjectsTypes

My Account

LoginRegister

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV